Cohort Study of Prospective Validation of Predictive Factors and Biological Imaging of Response to Bevacizumab (AVASTIN) in Combination With Weekly Paclitaxel Chemotherapy in First Line Treatment Patients With Metastatic Breast Cancer

Trial Profile

Cohort Study of Prospective Validation of Predictive Factors and Biological Imaging of Response to Bevacizumab (AVASTIN) in Combination With Weekly Paclitaxel Chemotherapy in First Line Treatment Patients With Metastatic Breast Cancer

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 09 Dec 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Paclitaxel
  • Indications Breast cancer
  • Focus Biomarker; Pharmacodynamics; Pharmacogenomic
  • Acronyms COMET
  • Most Recent Events

    • 09 Dec 2017 Results assessing the heterogeneity and variability of HER2 expression on circulating tumor cells (CTC) in HER2 negative metastatic breast cancer patients treated with paclitaxel and bevacizumab (n=203) presented at the 40th Annual San Antonio Breast Cancer Symposium
    • 02 Jun 2017 Results (n=203) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 14 Jan 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top